pharmaphorum | News & views on pharma and biotech’s evolving …
WEBpharmaphorum is an online publication seeking to educate, inform, engage, & connect pharmaceutical industry leaders to thrive in healthcare’s evolving future.
News | Timely industry updates for pharma and biotech leaders
WEB2 days ago · pharmaphorum’s news coverage updates daily with the latest pharma and biotech stories, from funding and M&A to regulatory approvals and policy shifts.
The booming medical device sector: How well are suppliers …
WEB4 days ago · Reviewing new international research, Peter Muller and Mike Baird of Schlafender Hase explore how Class 2 and 3 device manufacturers in Europe and the US are coping with rising Agency controls.
Bayer takes lung cancer therapy hope into phase 3
WEB3 days ago · News. Bayer has advanced its small-molecule drug BAY 2927088 into phase 3 for non-small cell lung cancer (NSCLC) with HER2 activating mutations, one of the drugs central to the company’s plan to ...
Views & Analysis | Perspectives on pharma industry issues
WEB3 days ago · Diverse and engaging perspectives on pharma developments and debates from pharmaphorum editors, industry insiders, and contributing experts.
Lilly’s Mounjaro wins latest head-to-head battle in clinical trials of ...
WEB2 days ago · Diabetes is one of the most common health conditions in the United States, afflicting more than 11% of the population, with over 90% included in the type 2 category. Mounjaro, manufactured by ...
Pharma | pharmaphorum
WEBAdvanz Pharma's bid to keep Ocaliva on EU market fails. The European Commission has followed the advice of its human medicines committee and revoked the conditional marketing authorisation for ...
pharmaphorum - The Deep Dive Digital Magazine has fresh …
WEBFeb 28, 2024 · Digital Health 2023. 29-11-2023 Deep Dive – Digital Health 2023 features interviews, analysis, and commentary from pharmaphorum, Lumanity, AXON, Viseven, Research Partnership, PurpleLeaf Strategy, M3, and more
Increasing sustainability in pharma requires an industry-wide effort
WEB5 days ago · After FDA no, MSD/Daiichi post new data with lung cancer ADC. MSD and Daiichi Sankyo's patritumab deruxtecan hit its main objective in a phase 3 lung cancer study that reinforces its potential as ...
Oncology | Tracking rapid innovation in cancer care
WEBSep 16, 2024 · From immunotherapy to cell and gene therapies to traditional small molecules, stay up to date on cancer care in pharmaphorum's dedicated oncology channel.